The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

At the moment of publication, the compound presented has been only approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of CKD associated with T2D in adults. For other approvals, follow your local regulations or health authorities legislation. The compound is not approved for non-diabetic CKD.

World Congress of Nephrology, 2022Industry Session Sponsored by Bayer February 24–27, 2022

Presentations of the Bayer Industry Symposium at WCN 2022

Thank you for your interest! Please see below to download PDFs of the presentation of the Bayer Industry Symposia at WCN 2022. Access to the presentations will be available after the congress presentation.

Finerenone

Saturday 26 February, 2022 | 09:35 - 10:00 CET
Nonsteroidal MRAs: Expanding the evidence base in CKD and T2D and exploring new opportunities

Cardiorenal benefits of finerenone across the CKD in T2D spectrum –Insights from FIDELITY

Session: Industry Sponsored SymposiumSpeaker: Meg Jardine

Doc Icon

Download the Slide Deck

Saturday 26 February, 2022 | 10:00 - 10:15 CET
Nonsteroidal MRAs: Expanding the evidence base in CKD and T2D and exploring new opportunities

Non-diabetic CKD –The next frontier for nonsteroidal MRAs?

Session: Industry Sponsored SymposiumSpeaker: Christoph Wanner

Doc Icon

Download the Slide Deck

The compendium provided by Bayer is a compilation of Bayer-sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from World Congress of Nephrology (WCN) and from the authors.

Reused with permission. © 2022 World Congress of Nephrology (WCN). All rights reserved.

For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR.

MA-M_FIN-ALL-0704-1

© 2022 Bayer AG

The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

 

At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

 

Last updated on 02/03/2022